Advancing Vaccines
For Better Lives
Welcome to Valneva
Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Our focused pipeline includes a single-shot chikungunya vaccine candidate currently in an ongoing Biologics License Application with the U.S. FDA, and the most advanced Lyme disease vaccine candidate currently in clinical development.
Check out our 2022 Annual Business Report
Follow Us
Valneva CEO Thomas Lingelbach speaks about the Company’s half-year results and plans for the rest of 2023
@ThomasLingelba1